Lilly's Alimta patent gets court backing; Sanofi's Lantus may fend off artery-thickening a bit;

 @FiercePharma: Interested in the new GSK site at Philly's Navy Yard? 22 pics of construction in progress--via Philadelphia Business Journal. Gallery | Follow @FiercePharma

> Eli Lilly's ($LLY) exclusivity on the lung-cancer drug Alimta was confirmed by a U.S. appeals court; Teva Pharmaceutical Industries ($TEVA) had argued the patent was invalid. Report

> Sanofi's ($SNY) diabetes treatment Lantus appeared to help stave off atherosclerosis in certain patients, researchers said, as the French drugmaker looks for ways to differentiate the drug from potential rivals. Report

> After losing key U.S. partners, India's Claris Lifesciences says it will fly solo in the market and market drugs through its U.S. subsidiary. Report

> AstraZeneca ($AZN) agreed to pay $26 million to settle a lawsuit with the attorney general of South Carolina, who had sought to recover funds spent to treat patients using the antipsychotic drug Seroquel. Report

> India's foreign investment approval board cleared 8 acquisition proposals from foreign drug companies, some of which had been languishing since March. Report

Medical Device News

@FierceMedDev: It's a good day to be CardioDx. The company pulled in $58M in new financing. News | Follow @FierceMedDev

 @MarkHFierce: Cook Medical opens a new plant today in Illinois. Article | Follow @MarkHFierce

 @DamianFierce: The first wave of renal denervation devices have impressed docs in the EU. Report | Follow @DamianFierce

> CardioDx pulls in $58M to expand Dx commercial sales. News

> Interleukin Genetics' founder returns to CEO slot. Item

Biotech News

 @FierceBiotech: Analysis: For Eli Lilly's solanezumab, take 2 doesn't look so pretty. More | Follow @FierceBiotech

 @JohnCFierce: FDA wants a rewrite on Lemtrada app? Bit of an embarrassment for Genzyme and its overseers at Sanofi. Report | Follow @JohnCFierce

 @RyanMFierce: Ex-Google guys eye clinical trials with startup Flatiron. Story | Follow @RyanMFierce

> Promising T-DM1 clears PhIII cancer study and marches on to the FDA. Story

> Idenix plunges after FDA puts another hep C treatment on hold. News

> ESC Roundup: Head-to-head flop for Eli Lilly, PhII bonus for Novartis cardio drug. More

Biotech IT News

> Groups craft algorithms to rank drug contenders. Story

> Sanofi takes wisdom of crowd in social media blitz. Item

> Ex-Google guys eye clinical trials with startup Flatiron. News

> Amazon targets pharma R&D, others with new cloud storage. More

> Boehringer sets launch date for pharma's first social game on Facebook. Article

CRO News

> Chinese CRO Tigermed completes $80M IPO. Item

> West to open CMO facility in India. Story

> Pfizer backs out of generics deal with India's Claris. News

> PRA expands its Chinese presence as market swells. Article

> Researchers bristle at India's proposed trial reforms. Story

And Finally... Middle-management dissatisfaction is a global phenomenon: healthcare and pharma staffers in India say they're underpaid and dissatisfied on the job. Report

Suggested Articles

Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.